看來載入頁面時發生了錯誤.
我們的團隊已收到通知,但若此問題持續,請透過電郵支援widget工具聯絡我們。
Metrics | Range | Conclusion |
---|---|---|
Selected LTM Pb Multiple | 2.2x - 2.5x | 2.4x |
Historical Pb Multiple | 2.1x - 2.9x | 2.4x |
Fair Value | €190.01 - €210.01 | €200.01 |
Upside | -9.5% - 0.0% | -4.8% |
Benchmarks | - | Full Ticker |
Quest Diagnostics Incorporated | - | NYSE:DGX |
Cryo-Cell International, Inc. | - | NYSEAM:CCEL |
Guardant Health, Inc. | - | NasdaqGS:GH |
OPKO Health, Inc. | - | NasdaqGS:OPK |
Precipio, Inc. | - | NasdaqCM:PRPO |
Labcorp Holdings Inc. | - | DB:N6B |
Select Price / Book Ratio | ||||||||
Benchmark Companies | ||||||||
DGX | CCEL | GH | OPK | PRPO | N6B | |||
NYSE:DGX | NYSEAM:CCEL | NasdaqGS:GH | NasdaqGS:OPK | NasdaqCM:PRPO | DB:N6B | |||
Historical Net Income Growth | ||||||||
5Y CAGR | 0.7% | -29.4% | NM- | NM- | NM- | -2.0% | ||
3Y CAGR | -24.2% | -42.2% | NM- | NM- | NM- | -30.2% | ||
Latest Twelve Months | 13.0% | 98.2% | 9.6% | 84.5% | 36.9% | 83.1% | ||
Historical Net Income Profit Margin | ||||||||
5 Year Average Margin | 12.9% | 0.0% | -94.8% | -14.8% | -103.9% | 9.5% | ||
Prior Fiscal Year | 9.2% | -30.4% | -85.0% | -21.9% | -38.5% | 3.1% | ||
Latest Fiscal Year | 8.8% | 1.3% | -59.0% | -7.5% | -23.1% | 5.7% | ||
Latest Twelve Months | 9.0% | -0.5% | -53.8% | -5.7% | -15.5% | 5.5% | ||
Return on Equity | ||||||||
5 Year Average Margin | 19.5% | 113.1% | -284.3% | -8.4% | -55.5% | 13.5% | ||
Prior Fiscal Year | 13.9% | NM | -438.1% | -12.8% | -38.1% | 4.2% | ||
Latest Twelve Months | 13.7% | NM | -1220.0% | -3.0% | -25.3% | 9.0% | ||
Next Fiscal Year | 15.7% | -2.5% | 82.8% | -22.8% | 87.8% | 16.0% | ||
Two Fiscal Years Forward | 15.6% | 1.9% | 34.4% | -30.5% | 67.5% | 15.7% | ||
Current Trading Multiples | ||||||||
Price / LTM Sales | 1.8x | 1.2x | 7.3x | 1.6x | 1.1x | 1.6x | ||
Price / LTM EPS | 20.3x | -226.7x | -13.5x | -28.5x | -7.0x | 28.7x | ||
Price / Book | 2.7x | -2.5x | -22.5x | 0.8x | 1.8x | 2.5x | ||
Price / Fwd Book | 2.6x | -2.1x | -12.1x | 1.1x | 0.7x | 2.3x | ||
Low | Mid | High | ||||||
Benchmark P/B Ratio | -22.5x | 0.8x | 2.7x | |||||
Historical P/B Ratio | 2.1x | 2.4x | 2.9x | |||||
Selected P/B Multiple | 2.2x | 2.4x | 2.5x | |||||
(x) Book Value | 8,307 | 8,307 | 8,307 |
Equity Value | |||||||
Benchmark Companies | |||||||
(in millions) | DGX | CCEL | GH | OPK | PRPO | N6B | |
Value of Common Equity | 19,222 | 39 | 5,636 | 1,110 | 22 | 20,638 | |
(/) Shares Outstanding | 111.8 | 8.1 | 123.9 | 793.1 | 1.5 | 83.7 | |
Implied Stock Price | 171.90 | 4.82 | 45.49 | 1.40 | 14.21 | 246.57 | |
FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |
Implied Stock Price (Trading Cur) | 171.90 | 4.82 | 45.49 | 1.40 | 14.21 | 210.00 | |
Trading Currency | USD | USD | USD | USD | USD | EUR | |
FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 |